These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3426 related articles for article (PubMed ID: 7332319)

  • 61. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
    J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of C3 acceptors responsible for complement activation in Crithidia fasciculata.
    Güther ML; Travassos LR; Schenkman S
    J Protozool; 1988 Nov; 35(4):475-80. PubMed ID: 3143825
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Third component of complement (C3): structural properties in relation to functions.
    Bokisch VA; Dierich MP; Mūller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1975 Jun; 72(6):1989-93. PubMed ID: 1056006
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ligand binding specificity of a rabbit alveolar macrophage receptor for C3b.
    Dixit R; Schneider R; Law SK; Kulczycki A; Atkinson JP
    J Biol Chem; 1982 Feb; 257(4):1595-7. PubMed ID: 6460027
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 66. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibition of neutrophil function by fluid phase C3b of complement.
    Ogle JD; Ogle CK; Alexander JW
    Infect Immun; 1983 Jun; 40(3):967-76. PubMed ID: 6221999
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The tick-over theory revisited: is C3 a contact-activated protein?
    Nilsson B; Nilsson Ekdahl K
    Immunobiology; 2012 Nov; 217(11):1106-10. PubMed ID: 22964236
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.
    Berger M; Fleisher TA
    J Immunol; 1983 Mar; 130(3):1021-3. PubMed ID: 6600466
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall.
    Winkelstein JA; Abramovitz AS; Tomasz A
    J Immunol; 1980 May; 124(5):2502-6. PubMed ID: 7365262
    [No Abstract]   [Full Text] [Related]  

  • 71. The role of C1s, C1r and properdin in the initiation of the C3b-dependent feedback mechanism of the complement system.
    Johnson U
    Acta Pathol Microbiol Scand C; 1978 Apr; 86(2):73-8. PubMed ID: 696332
    [TBL] [Abstract][Full Text] [Related]  

  • 72. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
    Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
    J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
    Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
    J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Binding of fluid-phase complement components C3 and C3b to human lymphocytes.
    Sim E; Sim RB
    Biochem J; 1981 Sep; 198(3):509-18. PubMed ID: 7326019
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.
    Pangburn MK; Müller-Eberhard HJ
    Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Activation and fixation of C3 by human B cell lines is enhanced by interferon-gamma and tumor necrosis factor alpha.
    Yefenof E; Algarra I; Ramos OF; Klein E
    Complement Inflamm; 1991; 8(5-6):271-80. PubMed ID: 1666351
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
    Lachmann PJ; Pangburn MK; Oldroyd RG
    J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
    Ramos OF; Kai C; Yefenof E; Klein E
    J Immunol; 1988 Feb; 140(4):1239-43. PubMed ID: 2963864
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of gangliosides on activation of the alternative pathway of human complement.
    Michalek MT; Bremer EG; Mold C
    J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 172.